Your browser is no longer supported. Please, upgrade your browser.
Settings
FLXN Flexion Therapeutics, Inc. daily Stock Chart
FLXN [NASD]
Flexion Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.48 Insider Own1.10% Shs Outstand40.24M Perf Week7.45%
Market Cap528.35M Forward P/E- EPS next Y-2.25 Insider Trans0.87% Shs Float36.30M Perf Month28.35%
Income-169.60M PEG- EPS next Q-1.05 Inst Own- Short Float23.01% Perf Quarter-9.07%
Sales30.90M P/S17.10 EPS this Y-8.00% Inst Trans-2.50% Short Ratio12.40 Perf Half Y-24.45%
Book/sh1.91 P/B6.87 EPS next Y43.50% ROA-54.10% Target Price26.44 Perf Year-52.70%
Cash/sh5.41 P/C2.43 EPS next 5Y- ROE-131.90% 52W Range9.65 - 29.10 Perf YTD15.99%
Dividend- P/FCF- EPS past 5Y-29.50% ROI-59.30% 52W High-54.88% Beta1.40
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin79.30% 52W Low36.06% ATR0.71
Employees272 Current Ratio6.30 Sales Q/Q381.80% Oper. Margin- RSI (14)61.63 Volatility5.44% 6.18%
OptionableYes Debt/Eq2.18 EPS Q/Q1.10% Profit Margin- Rel Volume0.58 Prev Close12.50
ShortableYes LT Debt/Eq2.02 EarningsMay 08 AMC Payout- Avg Volume673.53K Price13.13
Recom1.80 SMA2015.58% SMA5012.74% SMA200-14.66% Volume389,901 Change5.04%
May-09-19Upgrade The Benchmark Company Hold → Buy $19
Jan-04-19Reiterated Needham Buy $42 → $36
Jan-04-19Downgrade The Benchmark Company Buy → Hold
Jun-28-18Initiated The Benchmark Company Buy $39
Oct-09-17Reiterated Needham Buy $36 → $42
Aug-24-17Initiated Northland Capital Outperform
Dec-22-16Initiated Raymond James Strong Buy
Sep-06-16Resumed Lake Street Buy $38
Jul-21-16Initiated Lake Street Buy $38
May-03-16Resumed Wells Fargo Outperform
Nov-04-15Initiated Cantor Fitzgerald Buy
Sep-09-15Reiterated Needham Buy $31 → $28
May-14-15Initiated Northland Capital Outperform $40
Mar-31-15Initiated MLV & Co Buy $38
Aug-14-14Initiated Summer Street Research Buy $25
Mar-10-14Initiated Needham Buy $26
May-20-19 12:48PM  These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month Motley Fool
May-14-19 04:30PM  Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-12-19 09:50PM  Heres What Hedge Funds Think About Flexion Therapeutics Inc (FLXN) Insider Monkey
May-10-19 01:06PM  Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Call Transcript Motley Fool +8.74%
07:30AM  Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
May-09-19 11:58AM  Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today Motley Fool +19.32%
09:45AM  Chevron, Conduent, Flexion, and More: Stocks in the Spotlight Insider Monkey
01:34AM  Edited Transcript of FLXN earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 06:35PM  Flexion Therapeutics (FLXN) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.47%
05:25PM  Flexion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-02-19 09:00AM  Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International (OARSI) World Congress GlobeNewswire
May-01-19 04:30PM  Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-25-19 07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
Apr-24-19 04:30PM  Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Apr-23-19 12:53PM  Flexion Therapeutics, Inc. (NASDAQ:FLXN): Time For A Financial Health Check Simply Wall St.
Apr-05-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Apr-03-19 04:30PM  Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference GlobeNewswire
Apr-02-19 07:30AM  Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal Drugs GlobeNewswire
Apr-01-19 09:00AM  Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board GlobeNewswire
Mar-11-19 08:00AM  Mutual Fund Managers Are Bullish On Stock Market Forecast But Some Are Hedging Bets Investor's Business Daily
Mar-04-19 04:30PM  Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference GlobeNewswire -5.02%
07:00AM  Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors CNW Group
03:18AM  Edited Transcript of FLXN earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 04:45PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.73%
Feb-28-19 08:20PM  Flexion Therapeutics Inc (FLXN) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results GlobeNewswire
Feb-26-19 04:30PM  Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference GlobeNewswire
Feb-21-19 04:30PM  Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage GlobeNewswire
10:31AM  Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-20-19 04:30PM  Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Feb-12-19 09:46AM  Opening Bell, February 12, 2019 CNBC Videos
Feb-11-19 04:05PM  Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Rheumatology and Therapy GlobeNewswire
11:41AM  Here's Why Flexion Therapeutics Rose 29.8% in January Motley Fool
Feb-08-19 09:00AM  Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12 GlobeNewswire
Feb-01-19 05:00PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.74%
Jan-30-19 07:20AM  Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-22-19 04:30PM  Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer GlobeNewswire -5.14%
Jan-04-19 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.41%
07:59AM  The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO Benzinga
Jan-03-19 04:36PM  Flexion shares plummet after weak revenue guidance MarketWatch
04:01PM  Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019 GlobeNewswire
12:05PM  Raymond James: Flexion Therapeutics Estimates Are A Stretch Benzinga
10:26AM  Flexion Starts Phase III Enrollment on Zilretta for Hip OA Zacks
Jan-02-19 04:30PM  Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Hip and Reports Results from SHIP Study GlobeNewswire +10.07%
Dec-20-18 04:00PM  Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019 GlobeNewswire
Dec-17-18 04:30PM  Flexion Therapeutics Submits Supplemental New Drug Application (sNDA) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) GlobeNewswire
Dec-11-18 11:01AM  Here's Why Flexion Therapeutics Jumped 20.5% in November Motley Fool
Dec-04-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-18 10:07AM  2 Small Biotech Stocks That Insiders Are Buying TheStreet.com
Nov-27-18 01:53PM  Flexion Therapeutics Inc (NASDAQ:FLXN): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
08:45AM  New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-16-18 09:22AM  Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe GlobeNewswire
Nov-08-18 09:37PM  Edited Transcript of FLXN earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +19.06%
Nov-07-18 07:30PM  Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:34PM  Flexion Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports Third-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Nov-05-18 06:30AM  Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019 GlobeNewswire
Oct-31-18 07:30AM  Flexion Therapeutics to Report Third-Quarter 2018 Financial Results on November 7, 2018 GlobeNewswire -5.45%
Oct-22-18 07:30AM  Flexion Therapeutics to Present Results from Phase 2 Trial Evaluating ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Bilateral Knee OA at 2018 ACR Annual Meeting GlobeNewswire -9.08%
Oct-16-18 08:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within Iamgold, Mazor Robotics, Flexion Therapeutics, Hemisphere Media Group, Criteo S.A, and EP Energy New Research Emphasizes Economic Growth GlobeNewswire +6.23%
Oct-05-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-10-18 09:00AM  Flexion Therapeutics Announces Publication of Phase 2 Diabetes Data in September Issue of Rheumatology GlobeNewswire
Sep-07-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-28-18 04:30PM  Flexion Therapeutics to Present at the 2018 Wells Fargo Healthcare Conference GlobeNewswire +5.04%
Aug-20-18 05:23PM  Flexion Therapeutics Announces Presentation of Phase 3 Data at Military Health System Research Symposium GlobeNewswire
Aug-17-18 08:00AM  Report: Developing Opportunities within Adesto Technologies, BLACKLINE INC, Altice, Flexion Therapeutics, EZCORP, and CorVel Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-10-18 06:19AM  Note to Musk: Tesla isn't the only company targeted by short sellers. Here's who tops the list in Mass. American City Business Journals
Aug-07-18 06:35PM  Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:30PM  Flexion Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
02:30PM  Flexion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-30-18 04:30PM  Flexion Therapeutics to Report Second-Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-25-18 07:35AM  Free Technical Research on Evolus and Three More Generic Drugs Equities ACCESSWIRE -5.97%
Jul-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-21-18 09:00AM  Flexion Therapeutics Named one of Boston Business Journals Best Places to Work for the Second Year in a Row GlobeNewswire
Jun-19-18 07:15AM  Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks ACCESSWIRE
Jun-13-18 09:00AM  Alcami's Extended Workbench Supports Commercial Supply of Flexion Therapeutics's ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) PR Newswire
Jun-01-18 05:13PM  Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-29-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
May-10-18 03:46AM  Edited Transcript of FLXN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 05:37PM  Flexion Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
May-07-18 07:30AM  Flexion Therapeutics Names David Arkowitz as Chief Financial Officer GlobeNewswire
May-04-18 07:30AM  Flexion Therapeutics Announces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Recommended for Unique J Code by CMS GlobeNewswire
May-03-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-30-18 04:30PM  Flexion Therapeutics to Report First-Quarter 2018 Financial Results on May 8, 2018 GlobeNewswire
Apr-29-18 09:00AM  Flexion Therapeutics Announces Presentation of Positive FX201 Data at the Osteoarthritis Research Society International World Congress GlobeNewswire
Apr-26-18 07:30AM  Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at Osteoarthritis Research Society International World Congress GlobeNewswire +5.52%
Apr-24-18 04:30PM  Flexion Therapeutics to Present Data on ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) at the Academy of Managed Care Pharmacy Annual Meeting 2018 GlobeNewswire
Apr-18-18 04:20PM  Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery GlobeNewswire
Apr-06-18 04:30PM  Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:38AM  Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump Zacks
Apr-05-18 07:55AM  Detailed Research: Economic Perspectives on The Habit Restaurants, MUELLER WATER PRODUCTS, The Carlyle Group, Flexion Therapeutics, Hexcel, and Adesto Technologies What Drives Growth in Today's Competitive Landscape GlobeNewswire -5.25%
Mar-19-18 09:00AM  Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference GlobeNewswire
Mar-09-18 06:10PM  Edited Transcript of FLXN earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
04:15PM  Why A Key Drug Launch Wasn't Enough To Help This Biotech Stock Investor's Business Daily
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arkowitz DavidChief Financial OfficerMay 13Buy11.994,00047,96086,924May 15 04:05 PM
Clayman Michael D.President and CEOMay 10Buy12.484,01250,06774,868May 13 09:15 AM
Arkowitz DavidChief Financial OfficerMay 08Sale10.062,24822,61582,924May 09 04:32 PM
Clayman Michael D.President and CEOMar 12Buy12.364,04650,00970,856Mar 13 04:11 PM
Levine Mark S.General CounselJan 03Sale12.367349,0729,060Jan 04 05:12 PM
Wentworth KerryChief Regulatory OfficerJan 03Sale12.366227,68811,207Jan 04 05:10 PM
KELLEY SCOTTChief Medical OfficerJan 03Sale12.366227,68815,271Jan 04 05:09 PM
Bodick NeilChief Scientific OfficerJan 03Sale12.367469,22164,782Jan 04 05:06 PM
Clayman Michael D.President and CEOJan 03Sale12.363,27840,51666,810Jan 04 05:03 PM
Clayman Michael D.President and CEONov 09Buy17.105,00085,47769,166Nov 13 09:17 AM
Arkowitz DavidChief Financial OfficerNov 09Buy16.564,00066,22248,250Nov 13 09:14 AM
Arkowitz DavidChief Financial OfficerAug 09Buy23.424,00093,68044,250Aug 10 12:56 PM
Clayman Michael D.President and CEOAug 09Buy22.3310,000223,30075,282Aug 10 09:13 AM
Bodick NeilChief Scientific OfficerJul 03Sale25.0016,492412,30062,307Jul 03 04:07 PM
Bodick NeilChief Scientific OfficerJul 02Sale25.1033,508841,19278,799Jul 03 04:07 PM